Altimmune (ALT) Cash & Equivalents (2010 - 2026)

Altimmune (ALT) has 17 years of Cash & Equivalents data on file, last reported at $97.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $97.6 million, up 98.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $97.6 million (up 98.59% YoY), and the FY2025 annual result was $43.8 million, up 18.37% from the prior year.
• Cash & Equivalents grew to $97.6 million in Q1 2026 per ALT's latest filing, from $43.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $183.1 million in Q2 2025 and troughed at $31.5 million in Q3 2024.
• A 5-year average of $95.5 million and a median of $97.6 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 72.65% in 2024, then soared 220.29% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $111.1 million in 2022, then gained by 21.62% to $135.2 million in 2023, then sank by 72.65% to $37.0 million in 2024, then grew by 18.37% to $43.8 million in 2025, then soared by 123.04% to $97.6 million in 2026.
• Business Quant data shows ALT's Cash & Equivalents at $97.6 million in Q1 2026, $43.8 million in Q4 2025, and $61.3 million in Q3 2025.